Cargando…
Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials
Current approaches to assessing preclinical anticancer activity do not reliably predict drug efficacy in cancer patients. Most of the compounds that show remarkable anticancer effects in preclinical models actually fail when tested in clinical trials. We blame these failures on the complexity of the...
Autor principal: | López-Lázaro, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381701/ https://www.ncbi.nlm.nih.gov/pubmed/25859551 |
Ejemplares similares
-
The Challenge of Interpreting Alanine Aminotransferase Elevations in Clinical Trials of New Drug Candidates
por: Church, Rachel J., et al.
Publicado: (2020) -
Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
por: Selwood, D
Publicado: (2004) -
Anticancer drug development: preclinical screening, clinical trials and approval
por: Teicher, B A, et al.
Publicado: (2004) -
Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017) -
Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials
por: Bruinsmann, Franciele Aline, et al.
Publicado: (2019)